Boston Therapeutics, Inc.
| OTC Markets: BTHE
Boston Therapeutics, Inc. is a pharmaceutical company, which engages in the development, manufacture, and commercialization of novel compounds based on complex carbohydrate chemistry. Its products include therapeutic modules such as BTI320, Ipoxyn, and Oxyfex. The company was founded by David Platt and Kenneth A. Tassey Jr. on August 24, 2009 and is headquartered in Manchester, NH.